Search for a trial

A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma;

Primary objectives:(1) Evaluate Progression Free Survival (PFS) per RECIST 1.1 as assessed by blinded central radiologists' review in subjects with PD-L1 Combined Positive Score (CPS) *1. (2) Evaluate overall survival (OS).Secondary Objectives(…

Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer

The main objective is to compare overall survival of an active surveillance approach to that of standard surgery for patients with either squamous cell- or adenocarcinoma of the oesophagus or oesophago-gastric junction

Rectal preserving treatment for early rectal cancer. A multi-centred, partially randomised patient preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancers.

This study has been transitioned to CTIS with ID 2024-517410-15-01 check the CTIS register for the current data. The aim of this study is to determine the oncological safety, treatment related morbidity, and the functional outcome of local excision…

A Randomized, Active-Controlled, Blinded, Phase III Clinical Trial of BMS-986213 (Fixed Dose Combination of Relatlimab [anti-LAG-3] and Nivolumab) in Combination with Chemotherapy versus Placebo in Combination with Chemotherapy as First-Line Treatment in Participants with Unresectable, Locally Advanced or Metastatic LAG-3 Postive Gastric or Gastroesophageal Junction Adenocarcinoma

Primary ObjectivesThe main purpose of this study is to compare how long subjects with oesophageal cancer live overall (called overall survival, OS) or live without disease progression (called progression free survival, PFS) after receiving BMS-…